Eupraxia Pharmaceuticals Inc.
EPRX
$2.93
-$0.175-5.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.63% | -8.05% | -9.52% | -51.49% | -48.02% |
| Total Depreciation and Amortization | 10.42% | -1.06% | -0.19% | -2.75% | 1.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.93% | -102.04% | -132.43% | -65.30% | -20.45% |
| Change in Net Operating Assets | -226.40% | -221.60% | 1,363.61% | 679.67% | 251.72% |
| Cash from Operations | -44.56% | -56.08% | -44.83% | -35.82% | -39.06% |
| Capital Expenditure | -41.96% | -15.42% | 38.23% | 70.86% | 70.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.45% | -100.49% | -100.29% | -100.77% | -100.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11,408.19% | -9,066.97% | -3,512.08% | 52.19% | 55.44% |
| Issuance of Common Stock | 159.57% | 4.35% | 565.10% | 201.23% | 46.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 117.20% | -36.53% | 499.78% | 279.06% | 85.11% |
| Foreign Exchange rate Adjustments | -338.01% | 113.24% | 16.69% | 180.90% | 266.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,175.93% | -184.82% | 105.68% | 419.67% | -80.02% |
